Yuhan Corporation Collaborates with Samsung Seoul Hospital and I'mNeuron for New Drug Development
Signing of MOU for Research Cooperation on New Concept Therapeutic Technologies and Innovative Drug Development
[Asia Economy Reporter Kim Ji-hee] Yuhan Corporation announced on the 3rd that it has signed a Memorandum of Understanding (MOU) for research cooperation on new concept therapeutic technologies and innovative drug development with Samsung Seoul Hospital Future Medicine Research Institute and I'mNeuron Bioscience.
This MOU aims to realize personalized precision medicine for patients with rare and intractable diseases. Through this collaboration, the three institutions will promote ▲ exchange of medical and public health academic and technical information related to patient-tailored precision medicine for intractable diseases such as brain disorders, genetic diseases, and cancer ▲ discovery of projects and joint research through new concept therapeutic technologies ▲ mutual cooperation in innovative drug co-development.
The joint cooperation goal of personalized new concept therapies for patients with rare and intractable diseases is expected to be achievable by creating a one-stop new drug development ecosystem that spans from basic research to translational and clinical research, and commercialization.
To this end, the three institutions plan to discover new therapeutic targets and develop new concept therapeutic technologies, while conducting joint research cooperation to discover new drug candidate substances. Additionally, translational clinical research on drug candidates developed by Yuhan Corporation and I'mNeuron will also be conducted collaboratively.
Previously, in September last year, Yuhan Corporation signed a 'Industry-Academia Convergence Brain Disease R&BD Ecosystem Construction Cooperation Project' with Sungkyunkwan University and I'mNeuron. Within the Natural Science Campus of Sungkyunkwan University, efforts have been made to establish a 'CNS Research Center (tentative name)' to strengthen R&D capabilities for brain disease drug development by creating an industry-academia cooperation R&BD ecosystem.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Lee Jung-hee, CEO of Yuhan Corporation, stated, “To develop treatments for intractable diseases including brain disorders, an organic cooperation method among pharmaceutical companies, biotech firms, and hospitals that goes beyond existing open innovation is necessary. Through this agreement, which links new technologies essential for developing treatments for intractable diseases with translational research applicable to clinical practice, we will more efficiently develop treatments for intractable diseases and leap forward as a global company.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
